ERS International Congress, Madrid, 2019: Highlights from the Pulmonary Vascular Diseases Assembly

Overview

Journal ERJ Open Res

Specialty Pulmonary Medicine

Date 2020 Oct 21

PMID 33083438

Citations 2

Authors

Sheila Ramjug

Jason Weatherald

Sandeep Sahay

Johad Khoury

Vasile Foris

Nagaraj Chandran

Aleksandar Bokan

Laurent Godinas

Marion Delcroix

Affiliations

Soon will be listed here.

Abstract

The 2019 European Respiratory Society (ERS) International Congress, held in Madrid, Spain, had exciting sessions regarding the field of pulmonary vascular disease. The symposia related to the new ERS/European Society of Cardiology (ESC) Guidelines for the diagnosis and management of acute pulmonary embolism were well received, as were sessions on pulmonary hypertension related to lung disease, demonstrating the concept of pulmonary hypertension not being the rarity that it was previously thought to be. The use of risk stratification in relation to pulmonary arterial hypertension (PAH) was heavily featured and the scientific sessions informing the respiratory community of potential biomarkers and targets for future therapies were thought-provoking. This article discusses highlights of the 2019 pulmonary vascular disease sessions as a summary of current knowledge and practice. We have summarised the key points from the sessions pertaining to the new ERS/ESC Guidelines for the management of acute pulmonary embolism. We have also focused on prognostic factors and potential therapies in pulmonary hypertension related to interstitial lung disease. Relating to PAH, we have reviewed the symposia on risk stratification, along with the use of noninvasive measures and the sessions relating to biomarkers in PAH.

Citing Articles

ERS International Congress 2023: highlights from the Pulmonary Vascular Diseases Assembly.

Cullivan S, Boucly A, Jevnikar M, Lechartier B, Ulrich S, Bertoletti L ERJ Open Res. 2024; 10(1).

PMID: 38410705 PMC: 10895433. DOI: 10.1183/23120541.00847-2023.

Proteomic analysis of pulmonary arterial hypertension.

Qin X, Li T, Sun W, Guo X, Fang Q Ther Adv Chronic Dis. 2021; 12:20406223211047304.

PMID: 34729151 PMC: 8482352. DOI: 10.1177/20406223211047304.

References

Skoro-Sajer N, Mittermayer F, Panzenboeck A, Bonderman D, Sadushi R, Hitsch R . Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2007; 176(11):1154-60. DOI: 10.1164/rccm.200702-278OC. View

Young A, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C . Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018; 36(20):2017-2023. DOI: 10.1200/JCO.2018.78.8034. View

Howard L, Barden S, Condliffe R, Connolly V, Davies C, Donaldson J . British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE). Thorax. 2018; 73(Suppl 2):ii1-ii29. DOI: 10.1136/thoraxjnl-2018-211539. View

Connolly M, Garfield B, Crosby A, Morrell N, Wort S, Kemp P . miR-1-5p targets TGF-βR1 and is suppressed in the hypertrophying hearts of rats with pulmonary arterial hypertension. PLoS One. 2020; 15(2):e0229409. PMC: 7048278. DOI: 10.1371/journal.pone.0229409. View

Siques P, Brito J, Schwedhelm E, Pena E, Leon-Velarde F, De la Cruz J . Asymmetric Dimethylarginine at Sea Level Is a Predictive Marker of Hypoxic Pulmonary Arterial Hypertension at High Altitude. Front Physiol. 2019; 10:651. PMC: 6545974. DOI: 10.3389/fphys.2019.00651. View

Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer H . Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol. 2001; 37(4):489-92. DOI: 10.1097/00005344-200104000-00016. View

Olsson K, Richter M, Kamp J, Gall H, Heine A, Ghofrani H . Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2019; 38(7):748-756. DOI: 10.1016/j.healun.2019.05.002. View

Lang I, Simonneau G, Pepke-Zaba J, Mayer E, Ambroz D, Blanco I . Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. A case-control study. Thromb Haemost. 2013; 110(1):83-91. DOI: 10.1160/TH13-02-0097. View

Hoffmann J, Marsh L, Pieper M, Stacher E, Ghanim B, Kovacs G . Compartment-specific expression of collagens and their processing enzymes in intrapulmonary arteries of IPAH patients. Am J Physiol Lung Cell Mol Physiol. 2015; 308(10):L1002-13. PMC: 4437007. DOI: 10.1152/ajplung.00383.2014. View

10.

Negi V, Chan S . Discerning functional hierarchies of microRNAs in pulmonary hypertension. JCI Insight. 2017; 2(5):e91327. PMC: 5333972. DOI: 10.1172/jci.insight.91327. View

11.

Awerbach J, Stackhouse K, Lee J, Dahhan T, Parikh K, Krasuski R . Outcomes of lung disease-associated pulmonary hypertension and impact of elevated pulmonary vascular resistance. Respir Med. 2019; 150:126-130. DOI: 10.1016/j.rmed.2019.03.004. View

12.

Damico R, Kolb T, Valera L, Wang L, Housten T, Tedford R . Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2014; 191(2):208-18. PMC: 4347439. DOI: 10.1164/rccm.201409-1742OC. View

13.

Righini M, Robert-Ebadi H, Elias A, Sanchez O, Le Moigne E, Schmidt J . Diagnosis of Pulmonary Embolism During Pregnancy: A Multicenter Prospective Management Outcome Study. Ann Intern Med. 2018; 169(11):766-773. DOI: 10.7326/M18-1670. View

14.

Perisinakis K, Seimenis I, Tzedakis A, Damilakis J . Perfusion scintigraphy versus 256-slice CT angiography in pregnant patients suspected of pulmonary embolism: comparison of radiation risks. J Nucl Med. 2014; 55(8):1273-80. DOI: 10.2967/jnumed.114.137968. View

15.

Behr J, Kolb M, Song J, Luppi F, Schinzel B, Stowasser S . Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). Am J Respir Crit Care Med. 2019; 200(12):1505-1512. PMC: 6958532. DOI: 10.1164/rccm.201903-0488OC. View

16.

Nathan S, Barbera J, Gaine S, Harari S, Martinez F, Olschewski H . Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2018; 53(1). PMC: 6351338. DOI: 10.1183/13993003.01914-2018. View

17.

Righini M, van Es J, den Exter P, Roy P, Verschuren F, Ghuysen A . Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014; 311(11):1117-24. DOI: 10.1001/jama.2014.2135. View

18.

Henriksson P, Westerlund E, Wallen H, Brandt L, Hovatta O, Ekbom A . Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ. 2013; 346:e8632. PMC: 3546085. DOI: 10.1136/bmj.e8632. View

19.

Soon E, Treacy C, Toshner M, MacKenzie-Ross R, Manglam V, Busbridge M . Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax. 2011; 66(4):326-32. DOI: 10.1136/thx.2010.147272. View

20.

King C, Nathan S . Pulmonary hypertension due to interstitial lung disease. Curr Opin Pulm Med. 2019; 25(5):459-467. DOI: 10.1097/MCP.0000000000000599. View